Britains Pothole Crisis 186bn Backlog Highlights Infrastructure Investment Challenges SpaceX Starship Test A Critical Milestone Ahead of Potential IPO AnduraX Advances Reusable Spaceplane Development with Critical Drop Test Kiplinger Highlights Key Earnings Reports for May 2529 Week Biotech Stocks Face Headwinds but TopTier Names Show Resilience David Miliband Warns of Separate Bedrooms for USEurope Ties Potential Market Uncertainty BCAL Q1 2026 Earnings EPS Surprise of 276 Highlights Solid Performance Despite Minor Stock Decline Spectral AI Inc MDAI Q1 2026 Earnings WiderThanExpected Loss Despite Positive Stock Movement FCX Q1 2026 Earnings Strong EPS Beat Drives Positive Market Reaction Mativ Holdings MATV Q1 2026 Earnings EPS Surge of 194 Surprise Despite Flat Revenue Outlook PNNT Q1 2026 Earnings EPS Misses Estimates Despite Slight Stock Uptick ATLN Q4 2025 Earnings Significant EPS Miss Weighs on Stock Vistagen Therapeutics VTGN Holds Near Support After Minor Decline Legence Corp LGN Surges 659 as Buyers Test Key Resistance Levels Infinite Eagle Acquisition Corp Rights IEAGR Holds Steady at 020 as Trading Remains Rangebound 1st Source Corporation SRCE Holds Steady Near Midpoint Consolidation Phase Ahead BioVie Inc BIVI Declines 526 Testing Critical Support Near 137 Kevin Warshs Potential Fed Policy Shift A Slimmer Role in Wall Streets Plumbing Fortune Brands Innovations FBIN Q1 2026 Earnings EPS Falls Just Short of Estimates Despite Strong Stock Reaction Destiny Tech100 Inc DXYZ Gains 219 as Shares Approach Key Resistance Zone STWD Q1 2026 Earnings EPS Misses Estimates Amid Challenging CRE Environment RMBI Q1 2026 Earnings Solid EPS Performance Amid Quiet Quarter 5E Advanced Materials Inc FEAM Q1 2026 Earnings NarrowerthanExpected Loss as Cost Controls Gain Traction Tower Semiconductor Ltd TSEM Q1 2026 Earnings Robust EPS Beat Highlights Operational Discipline Amid Revenue Uncertainty ADM Q1 2026 Earnings EPS Beat Drives Modest Stock Gain Armata Pharmaceuticals ARMP Q1 2026 Earnings Steep EPS Miss as ClinicalStage Biotech Continues Heavy RD Spending INMD Q1 2026 Earnings EPS Misses Estimates by 1744 Amid Challenging Quarter